Povero M, Pradelli L, Serra A, et al. Cost-Effectiveness Analysis of Alirocumab in High Cardiovascular-Risk Patients in Italy. Farmeconomia. Health Economics and Therapeutic Pathways. 2021;22(1). https://doi.org/10.7175/fe.v22i1.1499